GTx, Inc. (NASDAQ: GTXI) is seeing shares trade sharply higher on a collaboration pact with Merck (NYSE: MRK). The biotech and drug giant pact is for research and development and a strategic collaboration for selective androgen receptor modulators (SARMs). This is a new class of drugs with the potential to treat age-related muscle loss (sarcopenia) as well as other musculoskeletal conditions.
This collaboration includes GTx’s lead SARM candidate, Ostarine™, which is currently being evaluated in a Phase II clinical trial for the treatment of muscle loss in patients with cancer, and establishes a broad SARM collaboration under which GTx and Merck will pool their programs and partner to discover, develop, and commercialize current as well as future SARM molecules. Merck will be responsible for all future costs associated with ongoing development and, if approved, commercialization of Ostarine and other investigational SARMs resulting from the collaboration.
GTx and Merck will combine their respective SARM research programs and GTx will receive an upfront payment of $40 million plus $15 million in research reimbursements to be paid over the initial three years of the collaboration. In addition, Merck will make an equity investment of $30 million in GTx common stock at a 40 percent premium to the 30 day average closing price. But the longer-term function of the contract is the real kicker. GTx will also be eligible to receive up to $422 million in future milestone payments associated with the development and approval of a drug candidate if multiple indications receive regulatory approval. Additional milestones may be received for the development and approval of other collaboration drug candidates. GTx will receive royalties on any resulting worldwide product revenue.
Shares of GTX Inc. are indicated up almost 20% at $17.27 pre-marklet, although it is on thin volume. The 52-week trading range is $10.53 to $23.64, and before this pop its market cap was $504 million. The last available short interest showed 2.77 million shares listed in the short interest, which is a whopping 23 days-to-cover ratio.
Jon C. Ogg
November 6, 2007
Jon Ogg can be reached at [email protected]; he does not own securities in the companies he covers.
Cash Back Credit Cards Have Never Been This Good
Credit card companies are at war, handing out free rewards and benefits to win the best customers. A good cash back card can be worth thousands of dollars a year in free money, not to mention other perks like travel, insurance, and access to fancy lounges. See our top picks for the best credit cards today. You won’t want to miss some of these offers.
Flywheel Publishing has partnered with CardRatings for our coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.